Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme

JAMA. 2005 Nov 23;294(20):2630-2. doi: 10.1001/jama.294.20.2630.

Authors

David A Henry¹, Suzanne R Hill, Anthony Harris

Affiliation

¹ School of Medicine and Public Health, University of Newcastle, New South Wales, Australia. david.henry@newcastle.edu.au

PMID: 16304078
DOI: 10.1001/jama.294.20.2630

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Australia
Cost-Benefit Analysis
Drug Costs*
Drug Evaluation*
Drug Industry / organization & administration*
Economics, Pharmaceutical
Humans
Insurance, Pharmaceutical Services*
Policy Making
Quality-Adjusted Life Years
State Medicine / economics*
Technology Assessment, Biomedical / economics
Technology Assessment, Biomedical / organization & administration*
Treatment Outcome
United Kingdom